<DOC>
	<DOCNO>NCT01229605</DOCNO>
	<brief_summary>The standard therapy patient locally advance breast cancer receive chemotherapy surgical removal tumor . This call neoadjuvant chemotherapy ( NAC ) . Chemotherapy use shrink tumor surgery , sometimes may allow small portion breast remove . Receiving chemotherapy surgery may sometimes also allow small portion breast remove . Getting chemotherapy prior surgery may also control hidden metastatic disease thereby decrease risk cancer relapse . Pre-surgery chemotherapy standard management approach locally advance breast cancer . Different combination drug use part pre-surgery chemotherapy . The purpose study determine use chemotherapy regimen TC effective way manage locally advance breast cancer ( Stage IIA- IIIB ) TC give surgery . The investigator also hope study help u good understand tumor tissue affect combination chemotherapy drug . The TC drug combination FDA approve use treat breast cancer , show equally effective commonly use chemotherapy regimen use surgery ; , TC drug combination yet study conjunction NAC use surgery . The investigator study combination TC use surgery mean possibly shrink tumor .</brief_summary>
	<brief_title>Cyclophosphamide Docetaxel Every 3 Weeks Neoadjuvant Therapy Locally Advanced Breast Cancer</brief_title>
	<detailed_description>This single-arm , open-label phase II study cyclophosphamide docetaxel/taxotere ( TC ) every 3 week Her2 ( - ) subject locally advanced breast cancer . It design ass ( 1 ) clinical pathologic response rate regimen , well tolerability subject population , ( 2 ) expression Tiam1 tumor-associated fibroblast pre post treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Women 18 year age old Histologically document adenocarcinoma breast , T2 ( T &gt; 2.0 cm ) N0 advance disease . No evidence metastatic disease . Disease must clinically radiographically measurable evaluable . Incisional core needle biopsy , yield sufficient tissue histologic confirmation adenocarcinoma , hormone receptor analysis Her2 testing ; Tiam1 expression . Subjects may receive prior chemotherapy breast cancer . Subjects may receive 3 month neoadjuvant hormonal therapy , provide restaged still eligible study , hormonal therapy least 48 hour . Subject must Her2 negative . Performance status 01 ECOG scale . Baseline laboratory value must follow : Absolute granulocyte count : great 1400/cells/ml ; Platelets : great 100,000 cells/ml ; Total bilirubin : le 1.5 mg/dl ; Serum ALT : less 2.5 x institutional upper normal limit ; Creatinine : le 1.6mg/dl ; Hemoglobin : great 9.0g/dl Subjects must nonpregnant nonlactating . Subjects childbearing potential must utilize effective method contraception study . Subjects receive chemotherapy 3 month neoadjuvant hormone therapy cancer . Subjects metastatic disease ( disease beyond breast , axillary node ipsilateral supraclavicular node ) inflammatory breast cancer ( T4d ) . Subjects active cancer , except nonmelanoma skin cancer Subjects active serious infection serious underlie medical condition would otherwise impair ability receive protocol treatment . Dementia significantly alter mental status would prohibit comprehension give informed consent . Pregnant breastfeeding woman ; sexually active , premenopausal woman willing use adequate method birth control . Subjects Her 2 neu positive exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>